Accession Number:



AXL-Targeting Antibody-Drug Conjugate as Novel Therapy for Triple-Negative Breast Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

Mayo Clinic

Personal Author(s):

Report Date:


Pagination or Media Count:



Our recent studies discovered that AXL, a receptor protein tyrosine kinase RTK, is selectively overexpressed and activated in highly aggressive TNBC cells. Based on this discovery in this study, we propose to establish AXL as a novel therapeutic target in the treatment of patients with TNBC. To achieve this, we will develop a novel therapeutic agent, a humanized anti-AXL ADC to specifically and effectively target TNBC with AXL overexpression. Specific Aims Aim 1. To develop a humanized antibody-drug conjugate ADC that can effectively target the AXL membrane receptor tyrosine kinase. Aim 2. To test the efficacy of the AXL-targeted ADC in preclinical animal models. Aim 3. To develop a mass spectrometry-based method to effectively monitor AXL expression and activation in xenograft tissues and clinical samples.

Subject Categories:

  • Genetic Engineering and Molecular Biology
  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]